Severe disease exacerbations in patients with multiple sclerosis after discontinuing fingolimod

Torkildsen, 2016, Disease-modifying treatments for multiple sclerosis – a review of approved medications, Eur J Neurol, 23, 18, 10.1111/ene.12883 Fitzgerald, 2015, Third PML case associated with fingolimod, Neurol Today, 15, 10, 10.1097/01.NT.0000472957.95553.c4 Ghezzi, 2013, Disease reactivation after fingolimod discontinuation in two multiple sclerosis patients, J Neurol, 260, 327, 10.1007/s00415-012-6744-7 Davion, 2016, Two cases of relapses in primary progressive multiple sclerosis after fingolimod withdrawal, J Neurol, 10.1007/s00415-016-8144-x Oskarsson, 2016, Myasthenia gravis exacerbation after discontinuing mycophenolate: a single-center cohort study, Neurology, 86, 1159, 10.1212/WNL.0000000000002405 Carey, 2006, Relapse, rebound, and psoriasis adverse events: an advisory group report, J Am Acad Dermatol, 54, S171, 10.1016/j.jaad.2005.10.029 Miravalle, 2011, Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy, Arch Neurol, 68, 186, 10.1001/archneurol.2010.257 Havla, 2012, Rebound of disease activity after withdrawal of fingolimod (FTY720) treatment, Arch Neurol, 69, 262, 10.1001/archneurol.2011.1057 Beran, 2013, Rebound exacerbation multiple sclerosis following cessation of oral treatment, Mult Scler Relat Disord, 2, 252, 10.1016/j.msard.2012.11.001 O’Connor, 2011, Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis, Neurology, 76, 1858, 10.1212/WNL.0b013e31821e7c8a Sorensen, 2014, Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients, J Neurol, 261, 1170, 10.1007/s00415-014-7325-8 De Vera, 2010, Pooled efficacy data demonstrate that fingolimod reduces multiple sclerosis relapse rate with no evidence of rebound after discontinuing treatment, Mult Scler, 16, S295 Gunduz, 2016, Withdrawal rebound after fingolimod in multiple sclerosis patients (P2.062), Neurology, 86, P2.062 Hatcher, 2016, Rebound syndrome in patients with multiple sclerosis after cessation of fingolimod treatment, JAMA Neurol Siger, 2011, Discontinuation of interferon beta therapy in multiple sclerosis patients with high pre-treatment disease activity leads to prompt return to previous disease activity, J Neurol Sci, 303, 50, 10.1016/j.jns.2011.01.016 Chun, 2010, Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis, Clin Neuropharmacol, 33, 91, 10.1097/WNF.0b013e3181cbf825 Johnson, 2010, Reconstitution of circulating lymphocyte counts in FTY720-treated MS patients, Clin Immunol, 137, 15, 10.1016/j.clim.2010.06.005 Cavone, 2015, Dysregulation of sphingosine 1 phosphate receptor-1 (S1P1) signaling and regulatory lymphocyte-dependent immunosuppression in a model of post-fingolimod MS rebound, Brain Behav Immun, 50, 78, 10.1016/j.bbi.2015.06.019 Yoshida, 2011, Relapse of experimental autoimmune encephalomyelitis after discontinuation of FTY720 (fingolimod) treatment, but not after combination of FTY720 and pathogenic autoantigen, Biol Pharm Bull, 34, 933, 10.1248/bpb.34.933 Berger, 2015, Severe disease reactivation in four patients with relapsing-remitting multiple sclerosis after fingolimod cessation, J Neuroimmunol, 282, 118, 10.1016/j.jneuroim.2015.03.022 Song, 2014, Peripheral blood T cell dynamics predict relapse in multiple sclerosis patients on fingolimod, PLoS One, 10, e0124923, 10.1371/journal.pone.0124923 McCarthy, 2010, Neurologic consequences of the immune reconstitution inflammatory syndrome (IRIS), Curr Neurol Neurosci Rep, 10, 467, 10.1007/s11910-010-0138-y Clifford, 2010, Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases, Lancet Neurol, 9, 438, 10.1016/S1474-4422(10)70028-4 Shelburne, 2002, Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy, Medicine (Baltimore), 81, 213, 10.1097/00005792-200205000-00005 Weinstock-Guttman, 2016, Randomised natalizumab discontinuation study: taper protocol may prevent disease reactivation, J Neurol Neurosurg Psychiatry, 10.1136/jnnp-2015-312221 Yamout, 2015, Safety and efficacy of reduced fingolimod dosage treatment, J Neuroimmunol, 285, 13, 10.1016/j.jneuroim.2015.05.012 Stone, 2002, Levels of IL-6 and soluble IL-6 receptor are increased in HIV patients with a history of immune restoration disease after HAART, HIV Med, 3, 21, 10.1046/j.1464-2662.2001.00096.x Reddy, 2014, An approach to control relapse of inflammatory lesions after discontinuation of primary therapy, PLoS One, 9, e98051, 10.1371/journal.pone.0098051 Araki, 2014, Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study, Neurology, 82, 1302, 10.1212/WNL.0000000000000317 Faissner, 2015, Tumefactive multiple sclerosis lesions in two patients after cessation of fingolimod treatment, Ther Adv Neurol Disord, 8, 233, 10.1177/1756285615594575 Kappos, 2015, Switching from natalizumab to fingolimod: a randomized, placebo-controlled study in RRMS, Neurology, 85, 29, 10.1212/WNL.0000000000001706 Edan, 2013, Induction therapy for patients with multiple sclerosis: why? When? How?, CNS Drugs, 27, 403, 10.1007/s40263-013-0065-y Gross, 2012, Multiple sclerosis rebound following herpes zoster infection and suspension of fingolimod, Neurology, 79, 2006, 10.1212/WNL.0b013e3182735d24 La Mantia, 2014, Multiple sclerosis rebound after fingolimod discontinuation for lymphopenia, Neurol Sci, 35, 1485, 10.1007/s10072-014-1800-y Hakiki, 2012, Withdrawal of fingolimod treatment for relapsing-remitting multiple sclerosis: report of six cases, Mult Scler, 18, 1636, 10.1177/1352458512454773 Sempere, 2013, Rebound of disease activity during pregnancy after withdrawal of fingolimod, Eur J Neurol, 20, e109, 10.1111/ene.12195 Alroughani, 2014, Multiple sclerosis reactivation postfingolimod cessation: is it IRIS?, BMJ Case Rep, 2014 De Masi, 2015, Dramatic recovery of steroid-refractory relapsed multiple sclerosis following fingolimod discontinuation using selective immune adsorption, BMC Neurol, 15, 125, 10.1186/s12883-015-0377-2